# Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

> **NCT00873223** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 33 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** insulin detemir

## Key facts

- **NCT ID:** NCT00873223
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00873223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00873223, "Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00873223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*